Radioligand Therapy Market to Grow with a CAGR of 5.31% through 2030

Growing incidences of prostate cancer and neuroendocrine tumors to drive the radioligand therapy market in the forecast period, 2026-2030.

According to TechSci Research report, “Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Radioligand Therapy Market was valued at USD 12.57 billion in 2024 and is expected to reach USD 17.15 billion by 2030 with a CAGR of 5.31% during the forecast period. The increase in incidences of different types of cancer, and rising product innovation and development due to technological advancements are the primary factors driving the demand for the global radioligand therapy market. Growing awareness of alpha radioimmunotherapy, rise in geriatric population, increasing radioisotopes in healthcare, and heavy investments in healthcare sector are expected to influence the market demand. Also, increasing strategic partnerships and collaborations and rising per capita health care expenditure are also a key factor for increasing the growth of the radioligand therapy market, globally.

However, the high cost associated with treatment and complex reimbursement processes, increased competition from generics may hamper the growth of the global radioligand therapy market may hamper the growth of the global radioligand therapy market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Radioligand Therapy Market"

The global radioligand therapy market is segmented into indication, product, biomarker, end user, regional distribution and company.

Based on Product, Lutathera (lutetium Lu 177 dotatate) shows the fastest growth in the global radioligand therapy market. Lutathera is specifically approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are rare but increasingly diagnosed due to better imaging technologies and heightened clinical awareness. According to the World Health Organization (WHO) and GLOBOCAN 2020, the incidence of neuroendocrine tumors has been steadily rising, with studies in the United States showing a six-fold increase in NET diagnoses over the past four decades. This growing patient population, coupled with the effectiveness of Lutathera in improving survival outcomes, has fueled its rapid adoption.

Based on the Region, The Asia-Pacific region is witnessing the fastest growth in the global radioligand therapy (RLT) market, fueled by rising cancer incidence, increasing healthcare investments, and rapid adoption of nuclear medicine technologies. According to the World Health Organization (WHO), Asia accounts for nearly 50% of all new global cancer cases, with countries such as China, India, and Japan reporting some of the highest numbers. For example, GLOBOCAN 2020 estimated that China alone recorded 4.6 million new cancer cases, making it a prime market for advanced therapies like radioligand treatment, especially for prostate and neuroendocrine cancers where conventional therapies may be limited.

Major operating companies operating in Global Radioligand Therapy Market are:

• Novartis AG
• Johnson & Johnson
• Pfizer, Inc.
• Amneal Pharmaceuticals LLC.
• POINT Biopharma Global Inc
• Fusion Pharmaceuticals Inc.
• Clovis Oncology, Inc.
• Telix Pharmaceuticals Limited
• Lantheus Holdings, Inc.
• Progenics Pharmaceuticals

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“North America region dominates the market and is expected to maintain its dominance in the coming years due to the adoption of radioligand therapy products after FDA approval. The strongly established research and healthcare infrastructure, rising emphasis on research and development and clinical research activity for the treatment of cancer,  several increasing developmental strategies, rising awareness among population, and heavy investments by government in the region is another key factor.  Also, owing to numerous medical and pharmaceutical companies in the region are expected to propel the global Radioligand Therapy market growth” said Mr. Karan Chechi, Research Director of TechSci Research, a research based global management consulting firm.

“Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication (Prostate Cancer, Neuroendocrine Tumor, Others), By Product (Lutathera, Zytiga, Xtandi, Xofigo), By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of global radioligand therapy market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global radioligand therapy market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com